Sequential loss of tumor vessel pericytes and endothelial cells after inhibition of platelet-derived growth factor B by selective aptamer AX102 - Wikidata - awgldk - TriplyDB

Sequential loss of tumor vessel pericytes and endothelial cells after inhibition of platelet-derived growth factor B by selective aptamer AX102

Sequential loss of tumor vessel pericytes and endothelial cells after inhibition of platelet-derived growth factor B by selective aptamer AX102

http://www.wikidata.org/entity/Q35575875

about

Pericytes promote endothelial cell survival through induction of autocrine VEGF-A signaling and Bcl-w expression Contrasting actions of selective inhibitors of angiopoietin-1 and angiopoietin-2 on the normalization of tumor blood vessels The Foxc2 transcription factor regulates tumor angiogenesis Tumor refractoriness to anti-VEGF therapy Aptamers: A promising chemical antibody for cancer therapy Anti-angiogenic alternatives to VEGF blockade Endothelial cell-pericyte interactions stimulate basement membrane matrix assembly: influence on vascular tube remodeling, maturation, and stabilization Signaling pathways in the development of infantile hemangioma A role for a CXCR2/phosphatidylinositol 3-kinase gamma signaling axis in acute and chronic vascular permeability.DNA Aptamer Technology for Personalized Medicine.Targeting PDGF signaling in carcinoma-associated fibroblasts controls cervical cancer in mouse model Aptamers: from bench side research towards patented molecules with therapeutic applications.Angiopoietin-2 interferes with anti-VEGFR2-induced vessel normalization and survival benefit in mice bearing gliomas.Molecular mediators of angiogenesis.Targeting distinct tumor-infiltrating myeloid cells by inhibiting CSF-1 receptor: combating tumor evasion of antiangiogenic therapy.Recent progress on normal and malignant pancreatic stem/progenitor cell research: therapeutic implications for the treatment of type 1 or 2 diabetes mellitus and aggressive pancreatic cancer.Complementary actions of inhibitors of angiopoietin-2 and VEGF on tumor angiogenesis and growth.Dual role of pericyte α6β1-integrin in tumour blood vessels.Increased vascular delivery and efficacy of chemotherapy after inhibition of platelet-derived growth factor-B SDF-1α induces PDGF-B expression and the differentiation of bone marrow cells into pericytes The antiangiogenic 16K prolactin impairs functional tumor neovascularization by inhibiting vessel maturation.Cytosolic phospholipase A2 and lysophospholipids in tumor angiogenesis Microfluidic approaches to rapid and efficient aptamer selection.Targeting the PDGF signaling pathway in tumor treatment A Phase II study of pulse dose imatinib mesylate and weekly paclitaxel in patients aged 70 and over with advanced non-small cell lung cancer.Fibronectins in vascular morphogenesis Blocking SDF-1α/CXCR4 downregulates PDGF-B and inhibits bone marrow-derived pericyte differentiation and tumor vascular expansion in Ewing tumors.Pericyte requirement for anti-leak action of angiopoietin-1 and vascular remodeling in sustained inflammation Targeting vascular pericytes in hypoxic tumors increases lung metastasis via angiopoietin-2.Targeting pericytes with a PDGF-B aptamer in human ovarian carcinoma models.Pericytes contribute to airway remodeling in a mouse model of chronic allergic asthma The role of blood vessels, endothelial cells, and vascular pericytes in insulin secretion and peripheral insulin action.Expression of FOXC2 in renal cell carcinoma and its relationship to clinical pathological features Role of bone marrow-derived cells in angiogenesis: focus on macrophages and pericytes.Soluble receptor-mediated selective inhibition of VEGFR and PDGFRbeta signaling during physiologic and tumor angiogenesis.An Adam15 amplification loop promotes vascular endothelial growth factor-induced ocular neovascularization.Development and characterization of a high-throughput in vitro cord formation model insensitive to VEGF inhibition.Multivalent proteoglycan modulation of FGF mitogenic responses in perivascular cells.Clinicopathological significance of platelet-derived growth factor B, platelet-derived growth factor receptor-β, and E-cadherin expression in gastric carcinoma.Imatinib disrupts lymphoma angiogenesis by targeting vascular pericytes.

P2860

Q24595357-8579BF27-E2BA-422E-9298-1F6BA2DFE4D6 Q24644150-6355E4DD-799B-4517-8DC2-A0D5E10AA5D9 Q24647592-41A20C3B-2C32-4DDC-9220-A9B0A00EE4BB Q26747678-A3615751-D561-4B3D-9533-CAA7DBBFBEEE Q26766832-730D3D4E-AB65-4121-85B4-7E392415F110 Q26775947-6BFEEF09-B49B-4272-B220-70AAEC125A35 Q26852191-D0C4159E-58A2-43FB-BE07-3E2781895A98 Q26996608-EA49C5E0-A9BD-462C-B24B-7AF080441EFC Q28566820-96FD2AFE-99CB-4BF2-A1E0-44FE9D2E2C0D Q30412965-310E0525-E661-415A-A6A8-EDD82F3D0F9F Q33317350-C073B3BF-CF1F-4A99-AA11-BDA05CB0B747 Q33512089-E0E13B5E-A41A-4FC7-83D9-C191CADB084A Q33587106-13F45135-6891-4535-B7BE-45DA89D11F8B Q33639474-25F623E1-E2A5-4C39-AEA2-BC6B14936F66 Q33680309-A1F9868A-3BEF-4530-AF6F-781A20570E1F Q33719099-247E557B-4BBF-4456-BE74-452DF8593FEA Q33732486-E9A4093A-84BE-484B-9ECF-9F9955C713F7 Q33743181-20FE9285-2DA6-49DD-9795-CEB63FDE57B0 Q33922852-1AD2FC10-7AA2-4982-A2EF-D3ACA3BFC2F5 Q34017318-CF655F93-73D1-445F-86E8-173EBD20EA4E Q34075597-04E1D55D-8F87-419C-A3F6-436B50A4638B Q34145860-E1790255-316C-42F9-92A3-0CB56BE9ED25 Q34303936-A4A6B277-406B-4DF4-A016-9DF4E55268FE Q34393461-CFE7BFB3-18BD-4B75-A887-3D82431EBC21 Q34433040-CB27ED34-9C2E-49FB-9FA4-FB3D99600AA8 Q34604585-9C43045E-033F-4625-AFA7-56704D178D9F Q35054920-5127FBB1-0F7C-48BA-BFCD-1E4732C1AA29 Q35071289-5283FA80-C983-49B5-AED4-8E8B8BD53704 Q35126158-D3CBE4FB-0309-4EBD-A590-82D5C92BBC4D Q35163538-E3CB328E-0D9D-4301-99B5-E8FC56B08617 Q35275345-E112BC31-846E-4DE2-8995-BDA52D71F78F Q36003362-7EACF801-E461-4E36-B658-A712E21715A6 Q36183054-8DB2637D-2D68-434C-9273-C1E9CDFD320F Q36284948-72FD2509-279C-4656-BC9A-2D4210EF9814 Q36775480-22AAA033-EB7D-4F0D-B297-C9AAF118CF18 Q36804949-3715119A-34C0-4626-B446-4A362F498D62 Q36828050-2BE53906-F7A4-470C-B478-503EF5E68F00 Q36851279-1353003B-613C-4F31-9E09-A0BDA50B10E4 Q36936790-D8E057B0-AA1C-4B26-B53C-BA16FC802BBF Q36962682-A771E105-6AA4-4C98-A52A-29CDB33EFAB2

P2860

Sequential loss of tumor vessel pericytes and endothelial cells after inhibition of platelet-derived growth factor B by selective aptamer AX102

http://www.wikidata.org/entity/Q35575875

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

2007年论文

@zh

2007年论文

@zh-cn

name

Sequential loss of tumor vesse ...... r B by selective aptamer AX102

@ast

Sequential loss of tumor vesse ...... r B by selective aptamer AX102

@en

type

label

Sequential loss of tumor vesse ...... r B by selective aptamer AX102

@ast

Sequential loss of tumor vesse ...... r B by selective aptamer AX102

@en

prefLabel

Sequential loss of tumor vesse ...... r B by selective aptamer AX102

@ast

Sequential loss of tumor vesse ...... r B by selective aptamer AX102

@en

P1433

Q35575875-E9E2A40D-3307-4D22-9002-A78E21572519

P1476

Q35575875-DE9731BA-D3A4-4621-A7B6-BFB30A40B2F8

P2093

Q35575875-1D3926A7-6D04-40CB-A809-BBE134F97F12

Q35575875-22C5EB33-745D-44D4-955E-2FCAE018B3C5

Q35575875-6E2FF5F2-ADCE-47BD-9C16-ACD8CA1D60D6

Q35575875-AF0EC53E-D3F8-4CF2-B1DD-304E3645A0C9

Q35575875-AFFA378D-F92E-46D1-8668-846739E61F92

Q35575875-B0077271-7C4C-4293-AEA6-20CD0F4920E1

Q35575875-B5752473-A4C6-4971-9DB5-59CB54F59A0B

Q35575875-D1A8C885-C5C5-4313-9C14-9DD348EC9167

Q35575875-EFB69D76-980A-480B-9AC8-8410D4ADA27B

P2860

Q35575875-04C520D8-8296-4A14-9D16-879F83FB0203

Q35575875-0CD9E0D7-3D00-44F9-8105-20A72D301223

Q35575875-135A16DA-6DCD-4A2B-9D98-7F2468F6FB71

Q35575875-15B7DCA3-73F9-4EDB-90C8-BB64ABC455BA

Q35575875-1A5E0062-FCD5-4711-8732-762387974722

Q35575875-257E93EE-2EE7-4E56-87F3-63D7D0594DF3

Q35575875-31703777-1C37-469F-B5EF-F23EA4691E99

Q35575875-33CAA9B5-9EBE-4CBB-91E3-48983F8AA65F

Q35575875-361D3218-DD18-4CC9-AFA7-3429F7C721A8

Q35575875-445F37CE-96AB-44B7-B45A-3EA3C13AEA1F

P304

Q35575875-6D8DA308-BB3E-4CFA-964C-A422F1CD134E

P31

Q35575875-97C8EFE5-FE5B-4654-9795-F517981F725E

P356

Q35575875-C516D16B-CF4D-45D2-A878-2526D29E851B

P407

Q35575875-C6B85C1F-7C73-489B-8DB9-8C7630EB26A2

P433

Q35575875-173EE2D0-F2C5-418D-B9C2-12E2EC063433

P478

Q35575875-ED06B2C3-EA3A-41F0-9B68-7582CA39C018

P577

Q35575875-898A9DF6-9FBE-457C-903E-69FF408976FC

P698

Q35575875-B8C2084B-CE94-4F77-BF28-78A76E9DE9BB

P921

Q35575875-216791FA-582C-49FF-8E7A-6EE8BC3F55D6

Q35575875-E6F9FFB3-4C75-4EA2-894B-14A4425ACE56

P932

Q35575875-E4C777B5-12E7-4C69-96B6-D3E226473A6A

P356

0008-5472.CAN-07-0293

P1433

Cancer Research

P1476

Sequential loss of tumor vesse ...... r B by selective aptamer AX102

@en

P2093

Amy Haskell

http://www.w3.org/2001/XMLSchema#string

Barbara Sennino

http://www.w3.org/2001/XMLSchema#string

Beverly L Falcón

http://www.w3.org/2001/XMLSchema#string

David M Epstein

http://www.w3.org/2001/XMLSchema#string

Dilara McCauley

http://www.w3.org/2001/XMLSchema#string

Donald M McDonald

http://www.w3.org/2001/XMLSchema#string

Jeffrey C Kurz

http://www.w3.org/2001/XMLSchema#string

Thomas McCauley

http://www.w3.org/2001/XMLSchema#string

Tom Le

http://www.w3.org/2001/XMLSchema#string

P2860

Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors

Lack of pericytes leads to endothelial hyperplasia and abnormal vascular morphogenesis

Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis

Role of PDGF-B and PDGFR-beta in recruitment of vascular smooth muscle cells and pericytes during embryonic blood vessel formation in the mouse

Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy

Pericyte loss and microaneurysm formation in PDGF-B-deficient mice

A small molecule-kinase interaction map for clinical kinase inhibitors

Endothelial/pericyte interactions

Basement membranes: structure, assembly and role in tumour angiogenesis

Imaging of angiogenesis: from microscope to clinic.

P304

7358-7367

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/0008-5472.CAN-07-0293

http://www.w3.org/2001/XMLSchema#string

P407

P433

15

http://www.w3.org/2001/XMLSchema#string

P478

67

http://www.w3.org/2001/XMLSchema#string

P577

2007-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17671206

http://www.w3.org/2001/XMLSchema#string

P921

P932

4422164

http://www.w3.org/2001/XMLSchema#string